Treatment Resistant Depression Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034)

The treatment resistant depression market was valued at USD 3295.00 Million in 2024, driven by the advancements in treatment options across the 8 major markets. The market is expected to grow at a CAGR of 6.10% during the forecast period of 2025-2034, with the value likely to rise to USD 5956.75 Million by 2034.

Treatment Resistant Depression Market Overview

Treatment resistant depression is characterized by the presence of depression symptoms despite continuous treatment. It includes severe depressive symptoms such as anhedonia (reduced ability to experience pleasure), along with suicidal thoughts and ideation. Repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy, and vagus nerve stimulation may be used to treat the condition, depending upon the severity of the symptoms.

The treatment resistant depression market is driven by the increasing cases of depression and the growing awareness about mental health disorders. The rising demand for novel therapeutic approaches, including non-pharmacological interventions, is poised to aid market expansion. Moreover, supportive healthcare policies aimed at improving treatment access and increased investments in mental health services are projected to influence the market landscape.

Treatment Resistant Depression Market Growth Drivers

Increasing Prevalence of Treatment Resistant Depression is Driving Market Growth

Treatment resistant depression is a major cause of disability in the population worldwide and is anticipated to affect approximately 21 million adults in the United States alone. It is reported that roughly 30% of the estimated 280 million  individuals globally affected by major depressive disorder develop treatment resistant depression. Thus, the increasing cases of treatment resistant depression, where the patient fails to show adequate response to two or more oral antidepressants in a single depressive episode, is one of the primary growth drivers of the market.

Treatment Resistant Depression Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Increased Clinical Research to Affect the Market Landscape Significantly

Since treatment resistant depression is dormant to almost all medications and antidepressants, researchers have been actively involved in developing new and effective treatment strategies for the affected patients. In May 2023, the FDA approved Ketamine, a low-cost dissociative drug as an effective analgesic and general anaesthetic to be used in combination with electroconvulsive therapy (ECT). As per the results of the clinical trials, it was revealed that 55% of patients receiving ketamine while 41% of patients getting ECT showed a minimum 50% improvement in their symptoms. Further, Esketamine, a nasal spray, which is considered a more effective form of Ketamine, has demonstrated promising results in treating the condition. Thus, the rise in research activities is expected to boost the market growth in the coming years.

Integration of Technology in Mental Health Care Poised to Augment Treatment Resistant Depression Market Demand

The incorporation of technology into mental health care is a major market trend that is projected to augment the market demand. For instance, the adoption of telehealth services has improved access to care for individuals in remote areas or those with mobility issues. In addition, mobile health applications and online platforms are helping to enhance overall patient engagement and adherence to treatment.

Rise in Drug Approvals to Elevate the Treatment Resistant Depression Market Value

The FDA has approved Brexanolone (Zulresso) to treat postpartum depression, a severe form of treatment-resistant depression, and dextromethorphan-bupropion (Auvelity), which works by modulating the NMDA receptors involved in depression. With the increasing number of drug approvals, the market value for treatment resistant depression is anticipated to observe a noticeable increase in the forthcoming years.

Focus on Holistic Approaches to Boost Treatment Resistant Depression Market Size

One of the significant market trends is the growing recognition of holistic approaches to managing treatment resistant depression. Mindfulness-based stress reduction (MBSR) and other behavioral therapies are increasingly being integrated into treatment plans to address the psychological aspects of the condition, which is expected to improve patient outcomes and boost market size during the forecast period.

Treatment Resistant Depression Market Segmentation

Treatment Resistant Depression Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Type

• N-methyl-D-aspartate (NMDA)
• Antidepressants
• Antipsychotics
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by End User

• Hospitals & Clinics
• Retail Pharmacies
• Online Pharmacies

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Treatment Resistant Depression Market Share

Market Segmentation Based on Drug Type is Anticipated to Witness Substantial Growth

Based on the drug type, the market is segmented into N-methyl-D-aspartate (NMDA), antidepressants, antipsychotics, and others. NMDA receptor antagonists hold a high market value due to their rapid action and ability to induce lasting effects on depressive symptoms. Additionally, the growing demand for ketamine-based treatments and ongoing research into other NMDA receptor modulators are likely to support the growth of this segment.

Treatment Resistant Depression Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. With heightened awareness of mental health issues and the availability of skilled mental healthcare professionals, the United States is projected to lead the market share in the forecast period. The presence of key pharmaceutical companies working at bringing the latest therapies into the market is a vital growth factor in the country. The market also benefits from the presence of a proactive government along with several nonprofit organizations spreading relevant information on combating mental health issues. Further, there is a rising trend towards adopting wellness practices in addition to using medical interventions to treat the condition, which is likely to impact treatment resistant depression market growth.

The Asia Pacific region, especially Japan, is expected to experience exponential market growth in upcoming years. This growth can be attributed to the decreasing stigmatization of mental health conditions in the region. Moreover, there is significant emphasis on improving the healthcare infrastructure to offer better patient outcomes, which is poised to aid market expansion in the country.

Leading Players in the Treatment Resistant Depression Market

The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

Johnson & Johnson (Janssen Pharmaceuticals)

Janssen Pharmaceuticals is a prominent player in the market, with a strong focus on the development of innovative therapies for mental health disorders. In July 2024 , Johnson & Johnson reported the submission of a supplemental New Drug Application (sNDA) to the FDA for its SPRAVATO®(esketamine) CIII nasal spray for treatment-resistant depression.

Abbvie Inc.

Headquartered in North Chicago, Illinois, pharmaceutical company Abbvie is a key player in the market. The company holds a robust pipeline of psychiatric medications and is actively investing in clinical research to expand its portfolio.

Eli Lilly and Company

American pharmaceutical company Eli Lilly and Company is a dominant player in the mental health market, offering several antidepressants that can be used to manage treatment resistant depression. Its FDA-cleared drug Symbyax(R)  (olanzapine and fluoxetine HCl capsules) is widely used for the acute treatment of treatment-resistant depression.

Bristol-Myers Squibb

Headquartered in Princeton, New Jersey, global biopharmaceutical company Bristol-Myers Squibb has a strong presence in the market. The company is actively exploring new options for treatment resistant depression within its pipeline.

Other key players in the market include Sage Therapeutics, Inc., Takeda Pharmaceutical Company, Pfizer Inc., GSK plc, Axsome Therapeutics, Inc., and Neuronetics, Inc.

Key Questions Answered in the Treatment Resistant Depression Market Report

• What was the treatment resistant depression market value in 2023?
• What is the treatment resistant depression market forecast outlook for 2025-2034?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on drug type?
• What is the market breakup based on the route of administration?
• Who are the major end users in the market?
• What are the major factors aiding the treatment resistant depression market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• How do the prevalence and incidence of treatment resistant depression affect the market landscape?
• What are the major treatment resistant depression market trends?
• How does the advancement in treatment options impact the market size?
• Which drug type will dominate the market share?
• Which route of administration is expected to have a high market value in the coming years?
• Which end user is projected to contribute to the highest market growth?
• Who are the key players involved in the treatment resistant depression market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?